A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Ono Pharmaceutical Co. Ltd
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
AbbVie
Takeda
Shenzhen BinDeBio Ltd.
Chinese PLA General Hospital
Kanisa Pharmaceuticals
Kanisa Pharmaceuticals